Vimarsana
Biggest News Aggregation in the World

Benjamin Ungar News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Benjamin Ungar. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Benjamin Ungar Today - Breaking & Trending Today

New Research Reveals Genomic Profile of Seborrheic - Vimarsana News

New Research Reveals Genomic Profile of Seborrheic

These findings are the first to characterize the unique molecular profile of seborrheic dermatitis...

New Research Reveals Genomic Profile of Seborrheic Dermatitis and Answers Key Questions on Immune Response and Skin Barrier Dysfunction - Vimarsana News

New Research Reveals Genomic Profile of Seborrheic Dermatitis and Answers Key Questions on Immune Response and Skin Barrier Dysfunction

09.03.2024 - Findings show that seborrheic dermatitis is a unique inflammatory skin disease with its own molecular signatureSuggests skin barrier disruption in seborrheic dermatitis is distinct with its own disease-specific pattern SAN DIEGO, Calif., March 09, ... Seite 1

Eczema: How skin diseases can produce sleep disturbances - Vimarsana News

Eczema: How skin diseases can produce sleep disturbances

Researchers say skin diseases such as atopic dermatitis can cause itching and other effects that disturb a person's sleep

Cardiovascular disease associated with four dermatological inflammatory diseases - Vimarsana News

Cardiovascular disease associated with four dermatological inflammatory diseases

Patients with rosacea, alopecia areata, psoriasis or atopic dermatitis all face an elevated risk for cardiovascular disease, according to a study. A growing body of evidence has found that inflammatory skin diseases (ISDs) are associated with an increased risk for comorbidities, many of which fall under the umbrella of cardiovascular disease (CVD).

Source: healio.com
Remibrutinib exhibits long-term favorable safety profile for chronic spontaneous urticaria - Vimarsana News

Remibrutinib exhibits long-term favorable safety profile for chronic spontaneous urticaria

SAN ANTONIO — Remibrutinib displayed sustained efficacy for chronic spontaneous urticaria with a favorable safety profile over 52 weeks, according to data presented at the American Academy of Allergy, Asthma & Immunology Annual Meeting.“Treating these patients has a huge, huge impact on the patient’s well-being and quality of life,” Warner W. Carr, MD, FACP, FACAAI,

Source: healio.com